Nabriva Therapeutics (NBRV) Competitors Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock NBRV vs. RAPT, ENTA, KRRO, SLS, TIL, TVGN, LFVN, DERM, CLLS, and CRBUShould you be buying Nabriva Therapeutics stock or one of its competitors? The main competitors of Nabriva Therapeutics include Rapt Therapeutics (RAPT), Enanta Pharmaceuticals (ENTA), Korro Bio (KRRO), SELLAS Life Sciences Group (SLS), Instil Bio (TIL), Tevogen Bio (TVGN), Lifevantage (LFVN), Journey Medical (DERM), Cellectis (CLLS), and Caribou Biosciences (CRBU). These companies are all part of the "pharmaceutical products" industry. Nabriva Therapeutics vs. Its Competitors Rapt Therapeutics Enanta Pharmaceuticals Korro Bio SELLAS Life Sciences Group Instil Bio Tevogen Bio Lifevantage Journey Medical Cellectis Caribou Biosciences Rapt Therapeutics (NASDAQ:RAPT) and Nabriva Therapeutics (NASDAQ:NBRV) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, analyst recommendations, risk, valuation, dividends, media sentiment and institutional ownership. Does the media refer more to RAPT or NBRV? In the previous week, Rapt Therapeutics had 2 more articles in the media than Nabriva Therapeutics. MarketBeat recorded 2 mentions for Rapt Therapeutics and 0 mentions for Nabriva Therapeutics. Rapt Therapeutics' average media sentiment score of 0.94 beat Nabriva Therapeutics' score of 0.00 indicating that Rapt Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Rapt Therapeutics Positive Nabriva Therapeutics Neutral Do analysts rate RAPT or NBRV? Rapt Therapeutics presently has a consensus price target of $21.57, suggesting a potential upside of 89.56%. Given Rapt Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Rapt Therapeutics is more favorable than Nabriva Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rapt Therapeutics 0 Sell rating(s) 5 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.50Nabriva Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has higher valuation and earnings, RAPT or NBRV? Nabriva Therapeutics has higher revenue and earnings than Rapt Therapeutics. Rapt Therapeutics is trading at a lower price-to-earnings ratio than Nabriva Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRapt Therapeutics$1.53M123.02-$129.87M-$14.17-0.80Nabriva Therapeutics$35.59M0.00-$57.19M-$19.20N/A Which has more volatility and risk, RAPT or NBRV? Rapt Therapeutics has a beta of 0.01, indicating that its stock price is 99% less volatile than the S&P 500. Comparatively, Nabriva Therapeutics has a beta of 1.53, indicating that its stock price is 53% more volatile than the S&P 500. Do institutionals & insiders have more ownership in RAPT or NBRV? 99.1% of Rapt Therapeutics shares are held by institutional investors. Comparatively, 0.3% of Nabriva Therapeutics shares are held by institutional investors. 2.4% of Rapt Therapeutics shares are held by company insiders. Comparatively, 1.6% of Nabriva Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Is RAPT or NBRV more profitable? Rapt Therapeutics has a net margin of 0.00% compared to Nabriva Therapeutics' net margin of -148.11%. Rapt Therapeutics' return on equity of -67.92% beat Nabriva Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Rapt TherapeuticsN/A -67.92% -59.59% Nabriva Therapeutics -148.11%-365.53%-135.81% SummaryRapt Therapeutics beats Nabriva Therapeutics on 12 of the 16 factors compared between the two stocks. Get Nabriva Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NBRV and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NBRV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NBRV vs. The Competition Export to ExcelMetricNabriva TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$45.46M$887.58M$5.75B$9.76BDividend YieldN/A4.84%4.10%4.04%P/E Ratio0.001.1083.2726.59Price / SalesN/A26.93535.09111.49Price / CashN/A19.5637.4459.26Price / BookN/A6.5510.556.58Net Income-$57.19M-$5.07M$3.27B$265.95M Nabriva Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M0.0070RAPTRapt Therapeutics4.3476 of 5 stars$10.92-6.9%$21.57+97.6%-30.8%$180.57M$1.53M-0.7780ENTAEnanta Pharmaceuticals3.7798 of 5 stars$8.44+3.2%$21.67+156.9%-34.8%$180.32M$64.81M-1.95160KRROKorro Bio1.3824 of 5 stars$19.12-3.0%$86.83+354.1%-51.6%$179.56M$6.28M-1.9670News CoverageSLSSELLAS Life Sciences Group2.9036 of 5 stars$1.71-1.4%$7.00+310.6%+48.8%$179.54M$1M-5.3310Positive NewsTILInstil Bio3.5362 of 5 stars$25.41-12.0%$119.00+368.3%+93.5%$171.54MN/A-1.97410Positive NewsAnalyst ForecastTVGNTevogen Bio3.7536 of 5 stars$0.92-4.1%$10.00+982.3%+74.4%$169.91MN/A0.003LFVNLifevantage4.0011 of 5 stars$13.14-4.0%$30.50+132.0%+64.6%$165.46M$222.35M19.05260News CoverageUpcoming EarningsDividend AnnouncementDERMJourney Medical1.6611 of 5 stars$7.06+0.8%$10.83+53.5%+44.8%$164.45M$56.40M-18.5890Analyst RevisionCLLSCellectis2.8563 of 5 stars$2.95+1.8%$4.00+35.5%+7.5%$164.08M$56.30M-3.60290News CoveragePositive NewsGap UpCRBUCaribou Biosciences2.7516 of 5 stars$1.77-5.6%$6.67+277.7%-13.4%$163.43M$9.99M-0.99100 Related Companies and Tools Related Companies RAPT Alternatives ENTA Alternatives KRRO Alternatives SLS Alternatives TIL Alternatives TVGN Alternatives LFVN Alternatives DERM Alternatives CLLS Alternatives CRBU Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NBRV) was last updated on 8/31/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nabriva Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Nabriva Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NBRV Stock Alerts